Nephrology
M-A: Among patients with kidney failure treated with dialysis, mineralocorticoid receptor antagonists reduce cardiovascular and all-cause mortality without increasing the risk of hyperkalemia.
15 Jun, 2021 | 08:53h | UTCEfficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Patients with kidney failure have a high risk of cardiovascular diseases. This meta-analysis suggests that mineralocorticoid receptor antagonists might improve clinical outcomes of patients with kidney failure without a major increase in hyperkalemia risk https://t.co/o3aO3KK2S6 pic.twitter.com/5xuCgs6FbQ
— CJASN (@CJASN) June 14, 2021
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
14 Jun, 2021 | 08:27h | UTC
The furosemide stress test: current use and future potential.
11 Jun, 2021 | 08:12h | UTCThe furosemide stress test: current use and future potential – Renal Failure
Cohort study: the use of potentially inappropriate medications in adults with chronic kidney disease is common and linked to increased risk of hospitalization, mortality, and falls.
11 Jun, 2021 | 08:11h | UTCRisk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study – American Journal of Kidney Diseases (link to abstract – $ for full-text)
Commentary on Twitter
Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From @CRICStudyhttps://t.co/1NgaqcJF5g@Rasheeda_HallMD @cjdiamantidis @sankarnava @finkjc @UMmedschool @DukeKidney #CKD #VisualAbstract pic.twitter.com/PLouT1SL9d
— AJKD (@AJKDonline) June 2, 2021
ANCA-Associated Vasculitis: An Update.
4 Jun, 2021 | 10:23h | UTCANCA-Associated Vasculitis: An Update – Journal of Clinical Medicine
RCT: Among patients with ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage treated with Rituximab, a reduced-dose glucocorticoids regimen (prednisolone 0.5 mg/kg/d) was noninferior to a high-dose glucocorticoid regimen (prednisolone 1 mg/kg/d) for the induction of disease remission.
4 Jun, 2021 | 10:25h | UTC
Diagnosis and management of diabetes insipidus for the internist: an update
4 Jun, 2021 | 10:22h | UTC
Consensus report: Postoperative acute kidney injury in adult non-cardiac surgery.
25 May, 2021 | 08:34h | UTC
#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.
24 May, 2021 | 08:28h | UTCUltrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary: Renal Denervation for Resistant Hypertension Is Not Back on Track – “A systolic blood pressure (SBP) reduction of 4.5 mm Hg is not good enough—for an invasive procedure”. – Medscape (free registration required)
SPRINT Trial final report: targeting a systolic BP of less than 120 mm Hg in patients at increased CV risk is associated with improved CV and mortality outcomes but increases the risk of serious adverse events.
20 May, 2021 | 08:36h | UTC
ESC Comprehensive review: Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease.
20 May, 2021 | 08:26h | UTC
Commentary on Twitter
Learn about the management of hypokalemia: a comprehensive review from the ESC WG on cardiovascular pharmacotherapy https://t.co/MkwOZyvUJA@AgewallStefan @GianluSava #EHJPharmacotherapy #cardiotwitter pic.twitter.com/tUFVmycwHa
— European Society of Cardiology Journals (@ESC_Journals) May 15, 2021
Fluid-induced harm in the hospital: look beyond volume and start considering sodium. From physiology towards recommendations for daily practice in hospitalized adults.
19 May, 2021 | 08:32h | UTC
Series: Social determinants of health in people with kidney disease.
19 May, 2021 | 08:29h | UTCIntroduction: Social Determinants of Health in People with Kidney Disease
The Pathogenesis of Race and Ethnic Disparities
Social Determinants of Kidney Health
Reducing the Burden of CKD among Latinx
The Seen and the Unseen: Race and Social Inequities Affecting Kidney Care
Personal Experiences of Patients in the Interaction of Culture and Kidney Disease
Commentary on Twitter
A series of Perspective articles were written based on talks at the 2020 Alison Norris Symposium at the New York Academy of Medicine on Social Determinants of Kidney Health. Dr. Alan M. Weinstein & Paul L. Kimmel share an overview of the program and series https://t.co/TlG0mOzZs4
— CJASN (@CJASN) May 14, 2021
Large cohort study confirms the renal toxicities of anti-inflammatories, suggesting Ibuprofen may be the safest option among them.
19 May, 2021 | 08:28h | UTCComparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary: Study: Ibuprofen Found Safest NSAID for the Kidney – MPR
Commentary on Twitter
Comparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD
Read this new @CJASN study and listen to the accompanying podcast:https://t.co/GL1ITzh4O4 pic.twitter.com/lZGeFqfrDZ
— Am Soc Nephrology (@ASNKidney) April 29, 2021
AHA Scientific Statement: Evaluation and management of aortic stenosis in chronic kidney disease.
14 May, 2021 | 08:27h | UTC
Review: The incidence, risk, presentation, pathophysiology, treatment, and effects of perioperative acute kidney injury.
12 May, 2021 | 08:27h | UTC
A restrictive fluid management strategy shows promise for acute kidney injury in a pilot randomized controlled trial.
10 May, 2021 | 00:57h | UTC
Commentary on Twitter
REVERSE-AKI restrictive fluid management vs usual care among critically ill pts with #AKI (proper initial fluid resus), multicenter feasibility RCT:
restriction? ⬇️cumulative fluid balance#RRT ➡️13% vs 30%
diuretics ↔️
usual care? ⬆️adverse events#FOAMcc https://t.co/JdKDo1XeIf pic.twitter.com/P1sOCHjkCS— Intens Care Med (@yourICM) May 7, 2021
[#ACC21 – not published yet] 1 in 5 adults with high blood pressure also take a medicine that could be elevating their blood pressure.
10 May, 2021 | 00:58h | UTCHave high blood pressure? You may want to check your meds – American College of Cardiology
Commentary: Are You Taking a Med That’s Raising Your Blood Pressure? – HealthDay
RCT: Efficacy and safety of voclosporin for lupus nephritis – voclosporin + MMF + low dose corticosteroids achieved complete renal response at week 52 more often than MMF + low dose corticosteroids alone (41% vs. 23%).
10 May, 2021 | 00:48h | UTCEfficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.
6 May, 2021 | 09:01h | UTC
Commentary on Twitter
The studies of mRNA vax in people with transplants are getting bigger: still the same message. Some protection, but not enough. This time, 308 people with kidney transplants in Israel, BNT-Pfizer vaccine https://t.co/Otvt8F11my
— Hilda Bastian, PhD (@hildabast) May 6, 2021
Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.
6 May, 2021 | 09:03h | UTCOriginal Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
M-A: Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease – “a 5 mm Hg reduction of systolic BP reduced the risk of major CV events by about 10%, irrespective of previous diagnoses of CV disease, and even at normal or high–normal BP values”
3 May, 2021 | 05:29h | UTCCommentaries: Many more people could benefit from blood pressure-lowering medication – The Lancet AND Decisions about antihypertensive treatment should focus on reducing cardiovascular risk – The Lancet
AHA Statement: Management of Stage 1 Hypertension in Adults With a Low 10-Year Risk for Cardiovascular Disease – “There is a lack of randomized clinical trials that have evaluated CVD outcomes among individuals with stage 1 hypertension and a low 10-year ASCVD risk”
30 Apr, 2021 | 08:37h | UTCNews Release: If slightly high blood pressure doesn’t respond to lifestyle change, medication can help – American Heart Association
Top Things to Know: Management of Stage 1 Hypertension in Adults With a Low 10-Year Risk for Cardiovascular Disease – American Heart Association
Commentary: The Hypertension Pandemic: Need for a Strategic Evidence-based Response – American Heart Association
RCT: Reduced dose direct oral anticoagulants may be a safer option to vitamin K antagonists in hemodialysis patients with atrial fibrillation
27 Apr, 2021 | 09:27h | UTCSafety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial – Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
This study finds that patients on hemodialysis with atrial fibrillation experienced decreased cardiovascular events and major bleeding complications with direct oral anticoagulants compared with vitamin K antagonists https://t.co/6FOKkEXtfN pic.twitter.com/PD6qHaeZjT
— JASN_News (@JASN_News) March 22, 2021
Do you really need to drink 8 glasses of water a day? An exercise scientist explains why your kidneys say ‘no’
23 Apr, 2021 | 08:11h | UTC